Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode

Table 1 DMBA-induced mammary gland tumor formation in WT, CORT-KO and SST-KO mice by whole-mount analysis

	WT		CORT-KO		SST-KO
	LF (n = 39)	HF (n = 43)	LF (n = 33)	HF (n = 24)	LF (n = 23)	HF (n = 30)
Whole-mount analysis
Tumor	3 %	5 %	14 %^##	13 %	4 %^$	3 %^$
Hyperplasia	16 %	35 %^**	10 %	25 %^**	13 %	38 %^***
Normal	81 %	60 %^**	76 %	63 %	83 %	59 %^**
Percentage of mice that were not included in the study^a	35 %	24.5 %	21.4 %	40 %	30.3 %	23 %

**p <0.01, ***p <0.001, for mice fed a low fat (LF) diet vs high fat (HF) diet (within the same genotype); ^## p <0.01 in wild-type (WT) vs knockout (KO) mice (within the same diet group); ^$ p <0.05) in cortistatin (CORT)-KO vs somatostatin (SST)-KO (within the same diet group). ^aMice that died during the 3 weeks of 7, 12 dimethylbenz[α]anthracene (DMBA) administration or during the weeks immediately subsequent, due to the toxicity of this compound and/or the invasiveness of the method used to deliver DMBA, were not included in the study